Pfizer (PFE) stock prices updated...
 

Pfizer stock price, PFE

Pfizer stock chart:



Pfizer close price: 33.01

Stock price forecast:

UP TO +0.58%
Target: 33.20

Total forecasts: 89
Reached: 13 (14.61%)

Total Win: 4.57 (13.56%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90901415.56%5.120.17%2,508.81-0.01-0.00%5.110.17%
303100.00%0.000.00%1,023.310.000.00%0.000.00%
141500.00%0.000.00%495.150.000.00%0.000.00%
7800.00%0.000.00%264.080.000.00%0.000.00%

Showing 1-10 of 643 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-07-2533.0133.150000-00-00
2017-07-2433.0133.160000-00-00
2017-07-2333.0133.170000-00-00
2017-07-2233.0133.170000-00-00
2017-07-2133.0133.180000-00-00
2017-07-2033.0133.170000-00-00
2017-07-1933.0133.190000-00-00
2017-07-1833.0133.180000-00-00
2017-07-1733.0133.230000-00-00
2017-07-1633.0133.280000-00-00

Pfizer latest news:


  • 07/25/2017 15:36:13

    Adviser charged with insider trading on Pfizer-King deal pleads guilty

    NEW YORK, July 25 (Reuters) - A Long Island, New York, investment adviser accused of engaging in insider trading after being tipped off about Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc pleaded guilty on Tuesday, federal prosecutors said.

  • 07/04/2017 11:51:50

    Pfizer receives token payment to exit Brazil venture, sources say

    SAO PAULO (Reuters) - Pfizer Inc has agreed to exit Laboratório Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge of the matter said on Tuesday.

  • 06/20/2017 17:19:51

    Exelixis's Cabometyx Positive for First-Line Kidney Cancer

    Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets

  • 06/14/2017 11:27:11

    BRIEF-Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe

    * Pfizer receives exclusive commercialization rights in Europe for CRESEMBA, a novel treatment for potentially life-threatening fungal infections among immunocompromised patients

  • 05/17/2017 10:01:27

    Most Dow stocks are below their 50-day moving averages

    As the Dow Jones Industrial Average slips Wednesday below its 50-day moving average (MA), which many technicians use to define the short-term trend, 17 of its 30 components are also below their respective 50-day MAs. Of that total, shares of Boeing Co. and Merck & Co. Inc. are below their 50-day MAs after closing above them on Tuesday, while UnitedHealth Group Inc.'s stock was above its 50-day MA as recently as Monday. Of that total, Pfizer Inc. , Chevron Corp. , General Electric Co. , Intel Corp. , Verizon Communications Inc. , International Business Machines Corp. , Merck and Procter & Gamble Co. were also below their respective 200-day MAs, which are viewed as dividing lines between longer-term uptrends and downtrends. Exxon Mobil Corp.'s stock was below its 200-day MA, but was still above its 50-day MA. The Dow was down 237 points at 20743, below the 50-day MA at 20,783, but well above the 200-day MA at 19,547.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/10/2017 15:18:02

    Sangamo shares jump on Pfizer collaboration, quarterly results

    Sangamo Therapeutics Inc. shares surged after the gene therapy company reported a narrower-than-expected loss for the quarter and a collaboration with pharmaceutical giant Pfizer Inc. . Sangamo shares jumped 42% to $6.15 after hours. The company reported a first-quarter loss of 23 cents a share on revenue of $3.4 million. Analysts surveyed by FactSet had estimated a loss of 28 cents a share on revenue of $4 million. Separately, Sangamo said it will receive a $70 million upfront payment from Pfizer for a development and manufacturing collaboration for a hemophilia A treatment. Sangamo said it was eligible for up to $450 million in milestone payments under the deal.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/08/2017 10:37:31

    BRIEF-Pfizer says multi-year extension of collaboration with Bill & Melinda Gates Foundation, Children's Investment Fund Foundation

    * Co, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation announced multi-year extension of collaboration

  • 05/02/2017 11:07:48

    Pfizer beats 1Q profit forecasts, but sales slip

    Pfizer beat Wall Street's expectations for first-quarter profit, thanks to reduced spending on operations and legal and other costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica

  • 05/02/2017 10:58:09

    Prescription for growth at Pfizer? Analysts say deals

    (Reuters) - Pfizer Inc posted basically flat first-quarter earnings, prompting suggestions that the largest U.S. drugmaker needs to do deals in order to improve its growth prospects.

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX-0.15% | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |